Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$0.42 - $3.43 $246 - $2,009
-586 Reduced 2.92%
19,454 $8,000
Q2 2024

Jul 12, 2024

SELL
$1.92 - $2.71 $1,190 - $1,680
-620 Reduced 3.0%
20,040 $53,000
Q1 2024

Apr 17, 2024

BUY
$2.24 - $4.15 $46,278 - $85,739
20,660 New
20,660 $56,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $17.8M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Mirador Capital Partners LP Portfolio

Follow Mirador Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirador Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Mirador Capital Partners LP with notifications on news.